Tybourne Capital Management (Hk) LTD Taysha Gene Therapies, Inc. Transaction History
Tybourne Capital Management (Hk) LTD
- $34.5 Billion
- Q2 2025
A detailed history of Tybourne Capital Management (Hk) LTD transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Tybourne Capital Management (Hk) LTD holds 4,095,000 shares of TSHA stock, worth $11.1 Million. This represents 27.39% of its overall portfolio holdings.
Number of Shares
4,095,000
Previous 3,700,000
10.68%
Holding current value
$11.1 Million
Previous $5.14 Billion
83.93%
% of portfolio
27.39%
Previous 21.83%
Shares
4 transactions
Others Institutions Holding TSHA
# of Institutions
132Shares Held
152MCall Options Held
70KPut Options Held
4.7K-
Avoro Capital Advisors LLC New York, NY20MShares$54.4 Million0.45% of portfolio
-
Rtw Investments, LP New York, NY18.8MShares$51.1 Million0.43% of portfolio
-
Morgan Stanley New York, NY16.8MShares$45.8 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.7MShares$31.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$29.6 Million0.0% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $132M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...